A candidate vaccine against staphylococcal enterotoxin B (SEB) was developed using a Venezuelan equine encephalitis (VEE) virus vector. This vaccine is composed of a self-replicating RNA, termed "replicon," containing the VEE nonstructural genes and cis-acting elements and a gene encoding mutagenized SEB (mSEB). Cotransfection of baby hamster kidney cells with the mSEB replicon and 2 helper RNA molecules resulted in the release of propagation-deficient mSEB-VEE replicon particles (mSEB-VRPs). Mice inoculated subcutaneously with mSEBVRPs were protected (15 of 20 mice) from a challenge with 5 median lethal dose units of wildtype (wt) SEB. T cells from mice vaccinated with mSEB-VRP responded normally both in vitro to wt SEB and in recall response to the inactivated mSEB polypeptide. The profile of cytokines measured after challenge with wt SEB suggested that the mode of protection was predominantly Th1 dependent. Our results suggest that the VEE replicon is a practical and convenient model system for evaluating efficacy of vaccines for the control of bacterial diseases.
Numerous cases of food poisoning and hospital-acquired infection are caused by Staphylococcus aureus bacteria. Exotoxins produced by the organism cause severe gastrointestinal distress, diarrhea, and vomiting and also are a cause of potentially lethal toxic shock syndrome. These exotoxins, also called superantigens, cause disease by binding to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and T cell antigen receptors, resulting in the release of large amounts of proinflammatory cytokines [1, 2] . Cytokine release has been postulated to mediate the many toxic effects of the S. aureus superantigens. Previous research has shown that disruption of the binding of mutagenized (m) staphylococcal enterotoxin B (SEB) to MHC class II molecules resulted in the elimination of the superantigen activity of mSEB [3] . It was also found that vaccine prepared with purified mSEB protein and combined with adjuvant could protect mice and nonhuman primates from a lethal challenge of wild-type (wt) SEB [3] . We have explored the use of a replicon vector as an alternative to the protein-in-adjuvant approach for vaccination.
The replicon vaccine vector used in the present study is composed of an RNA replicon, derived from an attenuated Venezuelan equine encephalitis (VEE) virus, and a bipartite helper system for packaging the replicon into propagation-deficient VEE replicon particles (VRPs) [4] . Other studies utilizing VRPs that express other endogenous viral antigens reported protection and immunogenicity in guinea pigs, mice, or nonhuman primates [5] [6] [7] [8] . In this study, we cloned the gene encoding mSEB into the VEE replicon vaccine vector (mSEB replicon), assembled the mSEB replicon into VRPs (mSEB-VRPs), and assessed the mSEB-VRP vaccine for both in vitro and in vivo expression, immunogenicity, and efficacy. The results of this study demonstrate that the mSEB-VRP vaccine is capable of inducing efficient Th1-dependent, antibody-mediated protection in mice against an otherwise lethal challenge of wt SEB.
Materials and Methods
Preparation and characterization of mSEB-VRP vaccine. The design and construction of the VEE replicon vector system and the Lassa virus nucleocapsid (N) replicon have been described elsewhere [4] . The mSEB gene [3] was cloned into the VEE replicon plasmid as an Nde I blunt end-Eco RI overhanging end fragment, using a shuttle vector. Assembly of the replicons into VRPs was conducted as described elsewhere [4, 8] . Western blots were conducted as described elsewhere [8] . Proteins were separated on a NuPAGE 10% Bis-Tris gel using NuPAGE 3-(N-morpholino) propanesulfonic acid SDS running buffer (Invitrogen) and were detected using rabbit anti-SEB antiserum (Toxin Technologies), horseradish peroxidaseconjugated goat anti-rabbit antibody, and 3,3 0 ,5,5 0 -tetramethylbenzidine peroxidase membrane substrate, according to the manufacturer's instructions (Kirkegaard and Perry Laboratories). VRPs were titrated as described elsewhere [4, 8] . The VRP titers are expressed as focus-forming units, where 1 focus-forming unit is equivalent to 1 infectious unit (iu). VRP preparations were monitored for the generation of replication-competent VEE virus using a standard plaque assay, and no plaque-forming units were found in any VRP preparations.
Vaccination and challenge of mice. BALB/c mice were inoculate subcutaneously (sc) with 10 5 -10 7 iu of mSEB-VRP vaccine (200 mL) at 28-day intervals. Positive control mice were inoculated intramuscularly (im) with 10 mg of mSEB adsorbed to 0.28% aluminum hydroxide in PBS (Alhydrogel 50 mL; EM Sergeant Pulp and Chemical). Negative control mice were inoculated sc with 10 7 iu of the Lassa N-VRP. Serum samples for ELISA were obtained 1-2 days before each inoculation and 2-5 days before challenge. The mice were challenged intraperitoneally (ip) 28 days after the last inoculation with wt SEB (1.25 mg or 5 LD 50 units; Toxin Technologies) in 200 mL of PBS and then 4 h later with lipopolysaccharide B (40 mg; Difco Laboratories) in 200 mL of PBS injected ip [9] .
Serum antibody analysis. The quantity of antibody present in immunized animal serum was measured by ELISA [8] . Titers were defined as the reciprocal of the last dilution with an absorbance at 405 nm of > 0.1 after correction for background. Titers , 2.00 log 10 and .5.61 log 10 were estimated. Serum samples from individual animals were assayed in duplicate and used to calculate a geometric mean titer for the group. VEE plaque reduction neutralizing antibody titers (PRNT) were determined as described elsewhere [10] [11] . The end-point titer was determined to be the last dilution showing an 80% reduction in the number of plaques (PRNT 80).
T cell stimulation assays. Mice inoculated with 3 doses of mSEB-VRP vaccine, mSEB/aluminum hydroxide or Lassa N-VRP, as described above, were euthanized, and spleens were removed aseptically. Single-cell suspensions were prepared as described elsewhere [10] . The isolated mononuclear cells were cultured for 3 days with wt staphylococcal enterotoxin A (SEA) or wt SEB (Toxin Technologies) or for 5 days with mSEA or mSEB in 96-well plates (3-5 £ 10 5 cells/well) in media containing 2% pooled mouse serum and were pulsed (9 h) with 1 mCi of [ 3 H]thymidine (Amersham). DNA synthesis was assessed by liquid scintillation radioactivity (TopCount-NXT; Packard Instruments). Cytokine assays. Mice were inoculated with 3 doses of mSEB-VRP vaccine, mSEB/aluminum hydroxide, or Lassa N-VRP, as described above, and were challenged with wt SEB, followed 4 h later with LPS, and then were bled 2 and 4 h after LPS administration. Levels of serum interferon (IFN)-g and tumor necrosis factor-a were detected by ELISA, using a commercially available kit (Genzyme), according to the manufacturer's instructions. Mononuclear cells from vaccinated and control mice were also collected as described above and were cultured (7 days at 37 C in 5% CO 2 ) in 24-well cell culture plates. Culture supernatants (300 mL) were used for cytokine analyses.
Results
Packaging and expression of the mSEB replicon. The mSEB replicon was assembled into VRPs by using the bipartite helper system originally developed by Pushko et al. [4] . The amount of packaged mSEB replicon obtained in the cell culture supernatants ranged from 1:4 £ 10 7 iu/mL to 4:6 £ 10 7 iu/mL. Figure 1A shows a photomicrograph of baby hamster kidney (BHK) cells infected with mSEB-VRPs. The staining pattern was consistent with cytoplasmic expression and retention of the mSEB polypeptide. Extensive nuclear, golgi, or plasma membrane staining was not observed in BHK cells infected with mSEB-VRPs. Cell lysates generated from BHK cells infected with mSEB-VRPs contained large amounts of mSEB polypeptide that comigrated on polyacrylamide gels with mSEB protein expressed in Escherichia coli ( figure 1B) .
Effect of mSEB-VRP vaccine on antibody responses and protection against challenge with wt SEB. Table 1 shows the prechallenge ELISA titers and survival rates of BALB/c mice inoculated with 2 or 3 doses of mSEB-VRP vaccine, ranging from 10 5 to 10 7 iu/dose. An increase in antibody titer was observed after every inoculation of mSEB-VRP vaccine and also correlated with the amount of VRP vaccine administered. Three doses of 10 5 or 10 6 iu of mSEB-VRP vaccine provided some protection, whereas 3 doses of 10 7 iu of mSEB-VRP vaccine provided the best protection, with 15 of 20 mice surviving a lethal challenge of 5 LD 50 units of wt SEB. In addition, the mSEB-VRP vaccine, as well as the mSEB/aluminum hydroxide vaccine, protected the mice. The mSEB-VRP vaccine stimulated a dose-dependent antibody response in BALB/c mice, with protection correlating directly with serum ELISA titers to SEB. Results for the negative control mice are shown in table 2.
With regard to anti-VRP immune responses, the VEE neutralizing antibody titer measured in the prechallenge serum obtained from mice inoculated with 3 doses of either mSEB/aluminum hydroxide or 10 6 iu of mSEB-VRP vaccine was below the limits of detection (PRNT 80, , 40). Mice that received inoculations of 10 7 iu of mSEB-VRP vaccine also had a VEE neutralizing antibody titer below the limits of detection, except for 2 of the 20 mice. Because both mice survived challenge, the VEE neutralizing antibody titer did not appear to reduce the efficacy of the mSEB-VRP vaccine. By contrast, mice inoculated with the TC-83 or V3526 VEE vaccine typically develop neutralization titers of 16,260 and 15,520, respectively [12] .
T cell memory responses. Because superantigens such as wt SEB can induce T cell anergy, one potential mechanism of NOTE. ND, not determined; PRNT 80, plaque reduction neutralization titer determined to be the last dilution showing an 80% reduction in the no. of plaques observed in control wells.
a All mice were inoculated with 10 7 infectious units of Lassa virus nucleocapsid-Venezuelan equine encephalitis replicon particles. Inoculations were given 28 days apart.
b Nos. in parentheses indicate nos. of mice.
protection mediated by mSEB-VRP vaccine could be silencing of responding T cells by anergy [1] . However, T cells from the vaccinated mice (3 inoculations of 10 7 iu of mSEB-VRP vaccine) proliferated vigorously in response to wt SEB and wt SEA, suggesting no evidence of anergy. Immune recognition of recombinant proteins by T cells from the same mice then was investigated using mSEB and a control antigen, mSEA, which also is inactivated by site-specific mutations [1] . Memory T cell responses to mSEB (15,000 cpm of [ 3 H]thymidine incorporation) were strong and exhibited marginal cross-reactivity with mSEA polypeptide (7500 cpm of [ 3 H] thymidine incorporation). The intracellular synthesis of mSEB from the mSEB replicon in antigen-presenting cells was expected to stimulate a dominant Th1 response. To examine this possibility, splenic mononuclear cells were cultured with wt SEB or mSEB, and the cytokines released into the medium were measured. No detectable interleukin (IL)-4 was released in the recall response to mSEB, whereas . 70 pg/mL was present in culture supernatants of cells stimulated with wt SEB. Both wt SEB and mSEB induced substantial levels of IFN-g. Next, cytokines present in serum samples collected from vaccinated mice 2 h after challenge with wt SEB were measured. Mice inoculated with the recombinant mSEB/aluminum hydroxide had slightly lower levels of IL-4 than did mSEB-VRP-immunized mice (60 pg/mL and 180 pg/mL, respectively) but no detectable serum IFN-g. In contrast, both Lassa N-VRP-and mSEB-VRPvaccinated mice produced elevated levels of serum IFN-g in response to wt SEB challenge (7700 pg/mL and 7800 pg/mL, respectively). We concluded from these data that immune T cells primed by the mSEB replicon recognized soluble extracellular antigen and expressed Th1-like cytokines.
Discussion
Because robust levels of foreign protein are expressed in eukaryotic cells [4] , alphavirus replicons are excellent vaccine vectors for the transient expression of foreign genes in animals. By inserting the mSEB gene into the mSEB replicon, we were able to achieve high levels of mSEB polypeptide expression in eukaryotic cells, to elicit a strong antibody response in mice, and to protect the majority of those mice from the lethal effects of wt SEB. The level of protection induced in mice inoculated with mSEB-VRP vaccine was comparable to that achieved with mSEB combined with adjuvant, as described elsewhere [3] . Since the mSEB-VRP vaccine does not contain adjuvant and can be combined with other VRP vaccines [8] , multivalent vaccines can be formulated for use in humans to prevent S. aureus infections and other foodborne diseases such as botulism.
Since alphaviruses replicate in the cytoplasm of eukaryotic cells [13] , expression of the mSEB gene in the cytoplasm alleviates the difficulties imposed by conventional nuclear transcription (i.e., limiting or incompatible transcription factors, mRNA splicing, and transport of the mRNA out of the nucleus). The mSEB gene used in these studies was not superantigenic, thus allowing conventional antigen processing and presentation to occur. Previous studies have suggested that intracellular expression of some bacterial antigens favors Th1-and MHC class Imediated immunity [14] . Our data indicate that the immune response to the replicon-encoded SEB vaccine was also Th1-like, although this bias did not appear to have an adverse effect on immune protection from toxin challenge. Cytotoxic T cell recognition of SEB is not known to be relevant to immunity. Since the mSEB-VRP vaccine elicited a Th1-like response, this vaccine may prove to be useful for vaccinating humans against diseases (e.g., malaria or dengue) that may require both a cellular and a humoral immune response for protection.
Previous research using viruses as vaccine vectors has shown that animals vaccinated with such vectors often develop high neutralizing responses against the vector and weak immune responses against the foreign gene [15] . In these studies, anti-VEE neutralizing antibodies in the BALB/c mice were monitored and found to be below the level of detection, except for 2 of the 20 mice inoculated with 3 doses of 10 7 iu of mSEB-VRP vaccine, and these responses did not block the efficacy of the mSEB-VRP vaccine. Additional experiments currently in progress are evaluating the use of different VEE glycoproteins (i.e., wt glycoproteins or those containing attenuating mutations) to target the VRP to different immune effector cells, to increase the immunogenicity of the VRP vaccines. Our use of the VEE replicon as a vaccine vector for inducing immune responses against wt SEB also demonstrates that these prokaryotic genes can be accurately and efficiently expressed in eukaryotic cells and that such expression can elicit a protective immune response.
